Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.76 |
| ▸ | TACR1 | P25103 | 16/20 | 0.64 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015355 | 1.00 | GHSR (0.76) | GHSRTACR1NPY5R | |
| SCHEMBL29440089 | 1.00 | GHSR (0.76) | GHSRTACR1NPY5R | |
| SCHEMBL5016439 | 0.95 | GHSR (0.78) | GHSRTACR1NPY5R | |
| SCHEMBL5016442 | 0.95 | GHSR (0.78) | GHSRTACR1NPY5R | |
| SCHEMBL6802758 | 0.88 | GHSR (0.84) | GHSRTACR1 | |
| SCHEMBL5013809 | 0.87 | GHSR (0.76) | GHSRTACR1NPY5R | |
| SCHEMBL8843020 | 0.87 | GHSR (0.76) | GHSRTACR1NPY5R | |
| SCHEMBL7381269 | 0.87 | GHSR (0.76) | GHSRTACR1NPY5R | |
| SCHEMBL5013586 | 0.86 | GHSR (0.70) | GHSRTACR1NPY5R | |
| SCHEMBL5013587 | 0.86 | GHSR (0.70) | GHSRTACR1NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442706-B2 | Methods for treating sarcopenia with a growth hormone secretagogue | AMMONETT PHARMA, LLC | 2008-10-28 | — | — | US | claimed |
| US-20070219226-A1 | METHODS FOR TREATING SARCOPENIA WITH A GROWTH HORMONE SECRETAGOGUE | AMMONETT PHARMA, LLC | 2007-09-20 | — | — | US | claimed |
| EP-0615977-B1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO INC (US) | 2002-07-03 | — | — | EP | claimed |
| US-6194402-B1 | ADMINISTERING A COMPOUND TO STIMULATE THE EFFECTS OF SOMATOTROPINS TO PATIENTS AFTER ACUTE DECONDITIONING SUCH AS THAT WHICH MAY RESULT FROM IMMOBILIZATION, SURGERY, OR MAJOR INJURY, E.G., HIP FRACTURE; | MERCK & CO., INC. | 2001-02-27 | — | — | US | claimed |
| US-6043026-A | MIXTURE OF AN ESTROGEN RECEPTOR MODULATOR AND A GROWTH HORMONE SECRETAGOGUE | MERCK & CO., INC. (US) | 2000-03-28 | — | — | US | claimed |
| WO-1998046220-A1 | COMBINATION THERAPY FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | MERCK & CO., INC. (US) | 1998-10-22 | — | — | WO | claimed |
| US-5536716-A | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | claimed |
| WO-1995011029-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO., INC. (US) | 1995-04-27 | — | — | WO | claimed |
| EP-0615977-A1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO. INC. (US) | 1994-09-21 | — | — | EP | claimed |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-09-21 | — | — | US | disclosed |
| EP-3197482-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | Oxeia Biopharmaceuticals Inc. (US) | 2017-08-02 | — | — | EP | disclosed |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | OXEIA BIOPHARMACEUTICALS, INC. (US) | 2017-05-04 | — | — | US | disclosed |
| US-5652235-A | Method of using spiro piperidines to promote the release of growth hormone | MERCK & CO., INC. (US) | 1997-07-29 | — | — | US | disclosed |
| WO-1997021703-A1 | ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE | MERCK & CO., INC. (US) | 1997-06-19 | — | — | WO | disclosed |
| US-5536716-A | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO., INC. (US) | 1996-07-16 | — | — | US | disclosed |
| WO-1995011029-A1 | COMBINATION OF BISPHOSPHONATES AND GROWTH HORMONE SECRETAGOGUES | MERCK & CO., INC. (US) | 1995-04-27 | — | — | WO | disclosed |
| EP-0615977-A1 | Spiro piperidines and homologs which promote release of growth hormone | MERCK & CO. INC. (US) | 1994-09-21 | — | — | EP | disclosed |
| WO-1994013696-A1 | SPIRO PIPERIDINES AND HOMOLOGS WHICH PROMOTE RELEASE OF GROWTH HORMONE | MERCK & CO., INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266257-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY | ATP6V1B2, FABP7, GHSR | GHSR 3/4885TACR1 96/4885NPY5R 11/4885 |
| US-20200261541-A1 | METHODS OF TREATING MILD BRAIN INJURY | FABP7, PYGB, ATP6V1B2 | GHSR 47/4885TACR1 553/4885NPY5R 66/4885 |
| US-20170121385-A1 | METHODS OF TREATING NEURODEGENERATIVE CONDITIONS | HTT, SNCA, NLN | GHSR 64/4885TACR1 843/4885NPY5R 119/4885 |
| US-20170281732-A1 | METHODS OF TREATING MILD BRAIN INJURY | ATP6V1B2, GHSR, CRH | GHSR 2/4885TACR1 223/4885NPY5R 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.